Cargando…
Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
Background: Different antiemetic medications with or without aprepitant are recommended for moderately emetic-risk chemotherapy (MEC) depending on the emetic potential of chemotherapy agents, although the criterion for the use of aprepitant is still unclear. The present study was designed to compare...
Autores principales: | Iihara, Hirotoshi, Ishihara, Masashi, Fujii, Hironori, Yoshimi, Chiaki, Yamada, Maya, Suzuki, Akio, Yamaguchi, Kazuya, Futamura, Manabu, Yoshida, Kazuhiro, Itoh, Yoshinori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820733/ https://www.ncbi.nlm.nih.gov/pubmed/27053955 http://dx.doi.org/10.7150/jca.13637 |
Ejemplares similares
-
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy
por: Iihara, Hirotoshi, et al.
Publicado: (2015) -
Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective
por: Abe, Masakazu, et al.
Publicado: (2023) -
Mechanisms of Nausea and Vomiting: Current Knowledge and Recent Advances in Intracellular Emetic Signaling Systems
por: Zhong, Weixia, et al.
Publicado: (2021) -
Intravenous amisulpride: A safer and possibly effective anti-emetic for postoperative nausea and vomiting
por: Nair, Abhijit, et al.
Publicado: (2021) -
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study
por: Iihara, Hirotoshi, et al.
Publicado: (2023)